Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

doses of sitagliptin. Clinically meaningful interactions would not be expected with other sulfonylureas (e.g., glipizide, tolbutamide, and glimepiride) which, like glyburide, are primarily eliminated by CYP2C9. However, the risk of hypoglycemia from the co-administration of sitagliptin and sulfonylureas is unknown. Simvastatin: Single-dose pharmacokinetics of simvastatin, a CYP3A4 substrate, was not meaningfully altered in subjects receiving multiple daily doses of sitagliptin. Therefore, sitagliptin is not an inhibitor of CYP3A4-mediated metabolism. Thiazolidinediones: Single-dose pharmacokinetics of rosiglitazone was not meaningfully altered in subjects receiving multiple daily doses of sitagliptin, indicating that JANUVIA is not an inhibitor of CYP2C8-mediated metabolism. Warfarin: Multiple daily doses of sitagliptin did not meaningfully alter the pharmacokinetics, as assessed by measurement of S(-) or R(+) warfarin enantiomers, or pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of warfarin. Because S(-) warfarin is primarily metabolized by CYP2C9, these data also support the conclusion that sitagliptin is not a CYP2C9 inhibitor. Oral Contraceptives: Co-administration with sitagliptin did not meaningfully alter the steady-state pharmacokinetics of norethindrone or ethinyl estradiol. Effects of Other Drugs on Sitagliptin Clinical data described below suggest that sitagliptin is not susceptible to clinically meaningful interactions by co-administered medications: Metformin: Co-administration of multiple twice-daily doses of metformin with sitagliptin did not meaningfully alter the pharmacokinetics of sitagliptin in patients with type 2 diabetes. Cyclosporine: A study was conducted to assess the effect of cyclosporine, a potent inhibitor of p-glycoprotein, on the pharmacokinetics of sitagliptin. Co-administration of a single 100 mg oral dose of JANUVIA and a sin
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2
... BRANFORD, Conn., April 19, 2007 /PRNewswire-FirstCall/ --,CuraGen ... interim clinical data on intravenous belinostat,(PXD101), a ... treatment of cancer, are expected to be ... One oral and one poster presentation discussing ...
... WIRE)--Apr 18, 2007 - Critical,Therapeutics, Inc. (Nasdaq: ... a role in chronic inflammatory,autoimmune disease for ... mediator and nuclear DNA-binding protein, will be,published ... Immunology. The,publication demonstrates that HMGB1 is part ...
Cached Medicine Technology:CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 2CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 3CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 4CuraGen and TopoTarget Announce New Clinical Results With,Belinostat to be Reported at Upcoming Major Medical Meetings 5Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 2Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 3Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 4Critical Therapeutics Announces the Publication of New Preclincial,HMGB1 Data in Nature Immunology 5
(Date:7/9/2014)... The National Institute of Allergy and Infectious Diseases ... has launched an early-stage clinical trial of CRS3123, ... Clostridium difficile ( C. difficile ) infection. ... agent that inhibits C. difficile growth while sparing ... will enroll up to 30 healthy men and ...
(Date:7/9/2014)... poor printing on prescription labels handed out by ... errors in taking medication, according to new research ... National Institute for the Blind)., The study, published ... found that labels on prescription medications dispensed by ... for legibility. , By simply following recommended guidelines ...
(Date:7/9/2014)... A study published in the scientific journal ... Bonin, two researchers at Universit Laval, reveals that it ... method that involves rekindling pain so that it can ... means to alleviate chronic pain. , The researchers from ... universitaire en sant mentale de Qubec (IUSMQ) were inspired ...
(Date:7/8/2014)... and cardiovascular health as other healthy mature individuals, according ... Journal of Transplantation . The findings may provide some ... professionals caring for them. , Over the past two ... and older has become more common. Given the links ... removal of a kidney could make older donors vulnerable ...
(Date:7/8/2014)... A team of clinicians from Plymouth, UK, and Sydney, ... 10th July Australia) launched ACEmobile - a free-to-use app ... , ACEmobile is the first of its kind; an ... tool provides support through the whole process, meaning more ... out this type of assessment. Designed by clinicians for ...
Breaking Medicine News(10 mins):Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:Discovery of a new means to erase pain 2Health News:Study finds kidney donation safe for healthy older adults 2Health News:New app widens opportunities for dementia assessments 2Health News:New app widens opportunities for dementia assessments 3
... Aggression, testosterone and nepotism dont necessarily help one climb ... female can, according to new research on the social ... The study, published today in the journal Proceedings of ... status, reproductive physiology and group dynamics. , ...
... Hopkins researchers question government decision to lower requirements ... -- Challenging a recent U.S. government decision to ... heart transplant hospital, a new Johns Hopkins Medical ... from 10 transplants to 14 transplants a year. ...
... new study from the Monell Center increases understanding ... and vomiting that often afflict patients undergoing chemotherapy. ... new approaches to combat these debilitating side effects. ... nausea and vomiting that accompany chemotherapy treatment, we ...
... 30 AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology ... AMICAS are scheduled to,address investors at the UBS Global Healthcare Services ... WHEN: -- Tuesday, ... Presentation begins promptly at 11:30 a.m. (Eastern Time), ...
... 2008 Preventative heart healthcare gains strong momentum today ... involvement as the exclusive radiology provider for the High-Risk ... joint research effort to advance the understanding and management ... primary underlying cause of heart attacks and strokes. ...
... to Nutrition on the Go, an,innovative new program from Diet.com, ... 1,700 restaurants nationwide is available in,a flash through your cell ... item., Not cell phone savvy? No worries. You put ... you need help with, then send that info to,DIET1 (34381). ...
Cached Medicine News:Health News:Females decide whether ambitious males float or flounder 2Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: